UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ____________ Commission File Number 001-36306 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 20-817927 ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q3 2019 Earnings Conference Call November 12, 2019 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - Chief Executive Officer Pete Meyers - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Lachlan Hanbury-Brown - William Blair Operator Good day, and welcome to today's program. My name is Keith, and I'll be your conference operator. At this time, I'd like to w ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - CEO & Director Pete Meyers - CFO Conference Call Participants Ashley Ryu - RBC Capital Markets Brandon Folkes - Cantor Fitzgerald Operator Good day, and welcome to today's program. My name is Keith, and I'll be your conference operator today. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals Second Quarter 2019 Earnings Results Conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ____________ Commission File Number 001-36306 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 20-8179278 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ____________ Commission File Number 001-36306 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 20-8179278 (S ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q1 2019 Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - Founder and CEO David Pernock - President and Chief Commercial Officer Pete Meyers - CFO, Principal Financial Officer and Principal Accounting Officer Adrian Hepner - EVP and CMO Conference Call Participants Brandon Folkes - Cantor Fitzgerald Ashley Ryu - RBC Capital Markets Tim Lugo - William Blair Operator Good day and welcome to today's program. My name i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36306 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 20-8179278 (State or Other J ...

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Q4 2018 Earnings Conference Call February 28, 2019 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Scott Tarriff – Founder, Chief Executive Officer and Director David Pernock – President, Chief Commercial Officer Pete Meyers – Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer Conference Call Participants Dan Busby – Randall Brandon Folkes – Cantor Fitzgerald Operator Good day and welcome to today’s program. My name ...